Durable tumor regression and OS in patients with advanced MCC receiving pembrolizumab as first-line therapy;Paul Nghiem et al.
At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Paul Nghiem (University of Washington) presented data on patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy.
This is the longest observation to date of patients with advanced MCC receiving first-line anti-PD-1, which demonstrates durable tumour control, a favourable overall survival rate, and a manageable safety profile. To view the presentation, please click here (Attachment no. 1)